PANASONIC-CORPORATION
Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005399/en/
Panasonic sought the agreement with Ms. Osaka after observing that her values and perspectives on society deeply resonate with its own management philosophy, primarily with regard to the following three points:
First, Ms. Osaka takes social issues seriously, looking beyond tennis to share her views on what a better society would look like in her own words. The founder of Panasonic, Konosuke Matsushita, held the notion that a stable state of happiness comes only when both mental stability and material prosperity are secured. Based on this idea, the company endeavors to create an ideal society where all of us can enjoy lives that are both mentally fulfilling and affluent in the material sense.
Second, Ms. Osaka’s intense and powerful playing is a source of energy and courage for people all over the world. Panasonic has passed down the founder’s view that the mission of an enterprise is to achieve a prosperous society and to make people happy, and continues to work toward fulfilling a strong aspiration not only to provide products needed by society, but also to make customers who use them feel happy and uplifted.
And third, Ms. Osaka continues to grow and evolve as her magnificent track record being one of the world’s top athletes is the result of her tireless efforts to refine each and every move in the course of her daily training and matches. Panasonic also continues to grow and evolve in a range of fields, aiming to elevate its expertise for the benefit of customers and society and achieve constant evolution.
At this time, Panasonic and Ms. Osaka have concluded a brand ambassador agreement to join hands in an endeavor to create an ideal society for each and every person, positioning “A Champion. For Progress.” as our shared commitment.
Ms. Osaka has shown she has the courage to take action in the face of adversity. Panasonic will provide her with heartfelt support.
Reference:
- Panasonic’s management philosophy
https://www.panasonic.com/global/corporate/management/philosophy.html#section_02
- Why Panasonic Appointed Naomi Osaka
https://channel.panasonic.com/contents/33222/
- "A CHAMPION. FOR PROGRESS." - Naomi Osaka, a brand ambassador of Panasonic
https://channel.panasonic.com/contents/33217/
https://channel.panasonic.com/contents/33219/
(Short version)
Naomi Osaka
Profile:
Date of birth: October 16, 1997
Place of birth: Osaka City, Osaka
Height: 180 cm
Naomi Osaka was born to a Japanese mother and a Haitian-American father, who moved her to New York in the United States when she was three years old. She is now based in Florida.
Major achievements:
- 2013: Started her professional career in tennis
- July 2014: Qualified for the first time for the Women’s Tennis Association (WTA) Tour Championships in Stanford
- January 2016: Advanced to the third round at the Australian Open, her Grand Slam debut
- 2016: Also advanced to the third round at the French Open (Roland-Garros) and the US Open Tennis Championships, where she recorded a serve speed of 201.1 km/h
- September 2016: Toray Pan Pacific Open Tennis Tournament runner-up
- October 2016: Named “Newcomer of the Year” at the 2016 WTA Awards, becoming the first Japanese player to win the award
- March 2018: BNP Paribas Open champion
- August 2018: US Open Tennis Championships champion
- January 2019: Australian Open champion
- September 2019: China Open tennis champion
- September 2019: Toray Pan Pacific Open Tennis Tournament champion
- August 2020: US Open Tennis Championships champion
- February 2021: Australian Open champion
Current WTA Ranking: 2nd
Qualified to play at the Olympic Games Tokyo 2020 (Women’s tennis, singles)
About Panasonic
Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th anniversary in 2018, operates 522 subsidiaries and 69 associated companies worldwide and reported consolidated net sales of 6,698.8 billion yen for the year ended March 31, 2021. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. Learn more about Panasonic: https://www.panasonic.com/global
Source: https://news.panasonic.com/global/press/data/2021/06/en210624-3/en210624-3.html
Related Links
- Panasonic’s management philosophy
https://www.panasonic.com/global/corporate/management/philosophy.html#section_02
- Why Panasonic Appointed Naomi Osaka
https://channel.panasonic.com/contents/33222/
- "A CHAMPION. FOR PROGRESS." - Naomi Osaka, a brand ambassador of Panasonic
https://channel.panasonic.com/contents/33217/
https://channel.panasonic.com/contents/33219/
(Short version)
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005399/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 14:30:00 CET | Press release
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 14:00:00 CET | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 14:00:00 CET | Press release
Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 using a randomized, multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes across three indications: metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) in pre-chemotherapy and post-177Lu-PSMA radioligand therapy (RLT) settings AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling
Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 14:00:00 CET | Press release
Establishment of the London office follows Luma AI’s $900 million Series C investment led by HUMAIN - marking the company’s first major step towards international scale with plans to deepen partnerships across the UK, European Union, and Saudi Arabia in the first phase of expansion.Former Monks and WPP executive Jason Day was appointed Head of EMEA to launch Luma AI internationally and drive worldwide growth across creative, advertising, gaming, and entertainment sectors.Luma AI plans to add 200 new jobs in London in 2026. Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING
Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 13:30:00 CET | Press release
Eventbrite stockholders to receive $4.50 per share in cash Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after cl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom